Johnson & Johnson Stock Drops 1.18% Despite FDA Approval for IMAAVY Ranking 61st in Trading Volume

On May 1, 2025, Johnson & Johnson (JNJ) experienced a significant decline in its stock price, dropping by 1.18%. The trading volume for the day was 11.31 billion, marking a 24.53% decrease from the previous day and placing it at the 61st position in terms of trading volume for the day.

Johnson & Johnson received FDA approval for IMAAVY, a new treatment for generalized myasthenia gravis (gMG). This approval is significant as it expands the treatment options for patients aged 12 and above who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibodies. The approval is based on the VIVACITY-MG3 study, which demonstrated substantial improvements in MG-ADL and QMG scores, indicating better daily function and disease control.

IMAAVY, marketed as nipocalimab, is the second FcRn blocker approved for gMG, following rozanolixizumab. It offers broad applicability to patients with different antibody types. The approval includes a patient support program called IMAAVY withMe, which aims to provide quick access to treatment with minimal cost per infusion. The most common adverse events reported include respiratory infections, peripheral edema, and muscle spasms.

Johnson & Johnson's IMAAVY approval is a significant milestone in the treatment of gMG, offering a new option for patients and their families. The approval underscores the company's commitment to developing innovative treatments for autoimmune conditions, potentially strengthening its portfolio in this area.